{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T06:21:22Z","timestamp":1649139682746},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,9,14]],"date-time":"2013-09-14T00:00:00Z","timestamp":1379116800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Orthop Surg Traumatol"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1007\/s00590-013-1293-z","type":"journal-article","created":{"date-parts":[[2013,9,13]],"date-time":"2013-09-13T07:08:46Z","timestamp":1379056126000},"page":"29-37","source":"Crossref","is-referenced-by-count":3,"title":["Bisphosphonate-related osteonecrosis of the jaw in patients with breast cancer"],"prefix":"10.1007","volume":"25","author":[{"given":"Andrea","family":"Piccioli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,9,14]]},"reference":[{"issue":"6","key":"1293_CR1","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.ctrv.2012.02.002","volume":"38","author":"N Bundred","year":"2012","unstructured":"Bundred N (2012) Antiresorptive therapies in oncology and their effects on cancer progression. Cancer Treat Rev 38(6):776\u2013786","journal-title":"Cancer Treat Rev"},{"key":"1293_CR2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/978-3-642-21892-7_3","volume":"192","author":"M Gnant","year":"2012","unstructured":"Gnant M, Dubsky P, Hadji P (2012) Bisphosphonates: prevention of bone metastases in breast cancer. Recent Results Cancer Res 192:65\u201391","journal-title":"Recent Results Cancer Res"},{"issue":"5","key":"1293_CR3","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","volume":"88","author":"A Lipton","year":"2000","unstructured":"Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M, Seaman JJ (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88(5):1082\u20131090","journal-title":"Cancer"},{"issue":"9","key":"1293_CR4","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","volume":"9","author":"M Gnant","year":"2008","unstructured":"Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, K\u00e4ssmann H, Piswanger-S\u00f6lkner JC, Seifert M, Ploner F, Menzel C, Dubsky P et al (2008) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 9(9):840\u2013849","journal-title":"Lancet Oncol"},{"issue":"3","key":"1293_CR5","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/annonc\/mdm442","volume":"19","author":"M Aapro","year":"2008","unstructured":"Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, Crin\u00f2 L, Dirix L, Gnant M, Gralow J et al (2008) Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19(3):420\u2013432","journal-title":"Ann Oncol"},{"issue":"8","key":"1293_CR6","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/annonc\/mdn164","volume":"19","author":"P Hadji","year":"2008","unstructured":"Hadji P, Body JJ, Aapro MS, Brufsky A, Coleman RE, Guise T, Lipton A, Tubiana-Hulin M (2008) Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 19(8):1407\u20131416","journal-title":"Ann Oncol"},{"issue":"21","key":"1293_CR7","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","volume":"21","author":"BE Hillner","year":"2003","unstructured":"Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A et al (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21(21):4042\u20134057","journal-title":"J Clin Oncol"},{"issue":"12","key":"1293_CR8","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1111\/j.1532-5415.2011.03713.x","volume":"59","author":"J Shannon","year":"2011","unstructured":"Shannon J, Modelevsky S, Grippo AA (2011) Bisphosphonates and osteonecrosis of the jaw. J Am Geriatr Soc 59(12):2350\u20132355","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"1293_CR9","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","volume":"62","author":"SL Ruggiero","year":"2004","unstructured":"Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62(5):527\u2013534","journal-title":"J Oral Maxillofac Surg"},{"issue":"10","key":"1293_CR10","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1023\/A:1012506426440","volume":"12","author":"SP Jagdev","year":"2001","unstructured":"Jagdev SP, Purohit P, Heatley S, Herling C, Coleman RE (2001) Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol 12(10):1433\u20131438","journal-title":"Ann Oncol"},{"issue":"9","key":"1293_CR11","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","volume":"61","author":"RE Marx","year":"2003","unstructured":"Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61(9):1115\u20131117","journal-title":"J Oral Maxillofac Surg"},{"issue":"3","key":"1293_CR12","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1601-0825.2007.01381.x","volume":"14","author":"J Sarin","year":"2008","unstructured":"Sarin J, DeRossi SS, Akintoye SO (2008) Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis. Oral Dis 14(3):277\u2013285","journal-title":"Oral Dis"},{"issue":"1","key":"1293_CR13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200507073530120","volume":"353","author":"BG Durie","year":"2005","unstructured":"Durie BG, Katz M, Crowley J (2005) Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353(1):99\u2013102 discussion 199-102","journal-title":"N Engl J Med"},{"issue":"6","key":"1293_CR14","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1359\/jbmr.080205","volume":"23","author":"AO Hoff","year":"2008","unstructured":"Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K et al (2008) Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23(6):826\u2013836","journal-title":"J Bone Miner Res"},{"issue":"10","key":"1293_CR15","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.clinthera.2011.09.001","volume":"33","author":"M Nakhla","year":"2011","unstructured":"Nakhla M, Denker AE, Connor JD, Carpenter TO, Walson PD, Porras AG, Matthews CZ, Larson P, Freeman A, Wagner JA et al (2011) Bioavailability and short-term tolerability of alendronate in glucocorticoid-treated children. Clin Ther 33(10):1516\u20131523","journal-title":"Clin Ther"},{"issue":"4","key":"1293_CR16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.breast.2009.07.001","volume":"18","author":"T Fehm","year":"2009","unstructured":"Fehm T, Felsenberg D, Krimmel M, Solomayer E, Wallwiener D, Hadjii P (2009) Bisphosphonate-associated osteonecrosis of the jaw in breast cancer patients: recommendations for prevention and treatment. The Breast 18(4):213\u2013217","journal-title":"The Breast"},{"issue":"20 Pt 2","key":"1293_CR17","doi-asserted-by":"crossref","first-page":"6301s","DOI":"10.1158\/1078-0432.CCR-06-1211","volume":"12","author":"T Powles","year":"2006","unstructured":"Powles T, McCroskey E, Paterson A (2006) Oral bisphosphonates as adjuvant therapy for operable breast cancer. Clin Cancer Res 12(20 Pt 2):6301s\u20136304s","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1293_CR18","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1159\/000022233","volume":"38","author":"IJ Diel","year":"1998","unstructured":"Diel IJ (1998) Bisphosphonates in the adjuvant therapy of breast cancer\u2014pathophysiology, animal models, and clinical experiences. Gynakol Geburtshilfliche Rundsch 38(2):64\u201371","journal-title":"Gynakol Geburtshilfliche Rundsch"},{"issue":"6","key":"1293_CR19","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM199808063390601","volume":"339","author":"IJ Diel","year":"1998","unstructured":"Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M, Bastert G (1998) Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339(6):357\u2013363","journal-title":"N Engl J Med"},{"issue":"26","key":"1293_CR20","doi-asserted-by":"crossref","first-page":"4289","DOI":"10.1200\/JCO.2007.15.4997","volume":"26","author":"T Saarto","year":"2008","unstructured":"Saarto T, Vehmanen L, Blomqvist C, Elomaa I (2008) Ten-year follow-up of 3\u00a0years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer. J Clin Oncol 26(26):4289\u20134295","journal-title":"J Clin Oncol"},{"issue":"7","key":"1293_CR21","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","volume":"360","author":"M Gnant","year":"2009","unstructured":"Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, P\u00f6stlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V et al (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360(7):679\u2013691","journal-title":"N Engl J Med"},{"issue":"2 Suppl 7","key":"1293_CR22","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1053\/j.seminoncol.2006.03.022","volume":"33","author":"A Brufsky","year":"2006","unstructured":"Brufsky A (2006) Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update. Semin Oncol 33(2 Suppl 7):S13\u2013S17","journal-title":"Semin Oncol"},{"issue":"11","key":"1293_CR23","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1093\/annonc\/mdq217","volume":"21","author":"H Eidtmann","year":"2010","unstructured":"Eidtmann H, de Boer R, Bundred N, Llombart-Cussac A, Davidson N, Neven P, von Minckwitz G, Miller J, Schenk N, Coleman R (2010) Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-months results of the ZO-FAST Study. Ann Oncol 21(11):2188\u20132194","journal-title":"Ann Oncol"},{"issue":"7","key":"1293_CR24","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/sj.bjc.6605604","volume":"102","author":"RE Coleman","year":"2010","unstructured":"Coleman RE, Winter MC, Cameron D, Bell R, Dodwell D, Keane MM, Gil M, Ritchie D, Passos-Coelho JL, Wheatley D et al (2010) The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 102(7):1099\u20131105","journal-title":"Br J Cancer"},{"issue":"3","key":"1293_CR25","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ygyno.2008.11.029","volume":"112","author":"T Fehm","year":"2009","unstructured":"Fehm T, Beck V, Banys M, Lipp HP, Hairass M, Reinert S, Solomayer EF, Wallwiener D, Krimmel M (2009) Bisphosphonate-induced osteonecrosis of the jaw (ONJ): incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecol Oncol 112(3):605\u2013609","journal-title":"Gynecol Oncol"},{"issue":"34","key":"1293_CR26","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","volume":"23","author":"A Bamias","year":"2005","unstructured":"Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C et al (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23(34):8580\u20138587","journal-title":"J Clin Oncol"},{"issue":"7","key":"1293_CR27","first-page":"1391","volume":"35","author":"AA Khan","year":"2008","unstructured":"Khan AA, S\u00e1ndor GK, Dore E, Morrison AD, Alsahli M, Amin F, Peters E, Hanley DA, Chaudry SR, Dempster DW et al (2008) Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 35(7):1391\u20131397","journal-title":"J Rheumatol"},{"issue":"1","key":"1293_CR28","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.critrevonc.2008.10.009","volume":"71","author":"M Tubiana-Hulin","year":"2009","unstructured":"Tubiana-Hulin M, Spielmann M, Roux C, Campone M, Zelek L, Gligorov J, Samson J, Lesclous P, Laredo JD, Namer M (2009) Physiopathology and management of osteonecrosis of the jaws related to bisphosphonate therapy for malignant bone lesions. A French expert panel analysis. Crit Rev Oncol Hematol 71(1):12\u201321","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"1293_CR29","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1177\/175045891002001202","volume":"20","author":"M Chimutengwende-Gordon","year":"2010","unstructured":"Chimutengwende-Gordon M, Khan WS, Sidhu J, Longo UG, Maruthainar N (2010) Advanced trauma life support radiographic trauma series: part 2\u2013the chest radiograph. J Perioper Pract 20(12):430\u2013435","journal-title":"J Perioper Pract"},{"issue":"3","key":"1293_CR30","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.joms.2006.11.003","volume":"65","author":"Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws AeAoOaMS","year":"2007","unstructured":"Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws AeAoOaMS (2007) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65(3):369\u2013376","journal-title":"J Oral Maxillofac Surg"},{"issue":"4","key":"1293_CR31","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.oooo.2012.06.006","volume":"114","author":"C Schaudinn","year":"2012","unstructured":"Schaudinn C, Gorur A, Webster P, Jones AC, Neely M, Jelliffe RW, Le AD, Sedghizadeh PP (2012) Quantification by energy dispersive x-ray spectroscopy of alendronate in the diseased jaw bone of patients with bisphosphonate-related jaw osteonecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol 114(4):480\u2013486","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"1293_CR32","first-page":"CD003474","volume":"2","author":"MH Wong","year":"2012","unstructured":"Wong MH, Stockler, Pavlakis N (2012) Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev 2:CD003474","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"1293_CR33","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/annonc\/mdp261","volume":"20","author":"S Beslija","year":"2009","unstructured":"Beslija S, Bonneterre J, Burstein HJ, Cocquyt V, Gnant M, Heinemann V, Jassem J, K\u00f6stler WJ, Krainer M, Menard S et al (2009) Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 20(11):1771\u20131785","journal-title":"Ann Oncol"},{"key":"1293_CR34","first-page":"CD003474","volume":"3","author":"N Pavlakis","year":"2005","unstructured":"Pavlakis N, Schmidt R, Stockler M (2005) Bisphosphonates for breast cancer. Cochrane Database Syst Rev 3:CD003474","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"1293_CR35","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.critrevonc.2006.12.005","volume":"62","author":"R Weitzman","year":"2007","unstructured":"Weitzman R, Sauter N, Eriksen EF, Tarassoff PG, Lacerna LV, Dias R, Altmeyer A, Csermak-Renner K, McGrath L, Lantwicki L et al (2007) Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients\u2014May 2006. Crit Rev Oncol Hematol 62(2):148\u2013152","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10","key":"1293_CR36","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","volume":"22","author":"S Khosla","year":"2007","unstructured":"Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S et al (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Min Res 22(10):1479\u20131491","journal-title":"J Bone Min Res"},{"issue":"8","key":"1293_CR37","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","volume":"110","author":"F Saad","year":"2007","unstructured":"Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R (2007) Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 110(8):1860\u20131867","journal-title":"Cancer"},{"issue":"1","key":"1293_CR38","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-010-0866-3","volume":"122","author":"V Guarneri","year":"2010","unstructured":"Guarneri V, Miles D, Robert N, Dieras V, Glaspy J, Smith I, Thomssen C, Biganzoli L, Taran T, Conte P (2010) Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat 122(1):181\u2013188","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"1293_CR39","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.joms.2009.09.017","volume":"68","author":"TS Lazarovici","year":"2010","unstructured":"Lazarovici TS, Yahalom R, Taicher S, Schwartz-Arad D, Peleg O, Yarom N (2010) Bisphosphonate-related osteonecrosis of the jaw associated with dental implants. J Oral Maxillofac Surg Off J Am Ass Oral Maxillofac Surg 68(4):790\u2013796","journal-title":"J Oral Maxillofac Surg Off J Am Ass Oral Maxillofac Surg"},{"issue":"35","key":"1293_CR40","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M et al (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol Off J Am Soc Clin Oncol 28(35):5132\u20135139","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"15","key":"1293_CR41","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","volume":"365","author":"RE Coleman","year":"2011","unstructured":"Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, Gil M, Houston SJ, Grieve RJ, Barrett-Lee PJ et al (2011) Breast-cancer adjuvant therapy with zoledronic acid. New Eng J Med 365(15):1396\u20131405","journal-title":"New Eng J Med"},{"issue":"7","key":"1293_CR42","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(11)70122-X","volume":"12","author":"M Gnant","year":"2011","unstructured":"Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, Jakesz R, Seifert M, Hubalek M, Pristauz G et al (2011) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 12(7):631\u2013641","journal-title":"Lancet Oncol"},{"issue":"4","key":"1293_CR43","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.clbc.2011.02.001","volume":"11","author":"N Ngamphaiboon","year":"2011","unstructured":"Ngamphaiboon N, Frustino JL, Kossoff EB, Sullivan MA, O\u2019Connor TL (2011) Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with\/without bevacizumab. Clin Breast Cancer 11(4):252\u2013257","journal-title":"Clin Breast Cancer"},{"issue":"6","key":"1293_CR44","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.breast.2011.05.006","volume":"20","author":"X Pivot","year":"2011","unstructured":"Pivot X, Lortholary A, Abadie-Lacourtoisie S, Mefti-Lacheraf F, Pujade-Lauraine E, Lefeuvre C, Letessier S, Morvan P, Dur C, Frimat L (2011) Renal safety of ibandronate 6\u00a0mg infused over 15\u00a0min versus 60\u00a0min in breast cancer patients with bone metastases: a randomized open-label equivalence trial. Breast 20(6):510\u2013514","journal-title":"Breast"},{"issue":"5","key":"1293_CR45","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1524-4741.2011.01119.x","volume":"17","author":"D Quispe","year":"2011","unstructured":"Quispe D, Shi R, Burton G (2011) Osteonecrosis of the jaw in patients with metastatic breast cancer: ethnic and socio-economic aspects. Breast J 17(5):510\u2013513","journal-title":"Breast J"},{"issue":"5","key":"1293_CR46","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ejca.2010.11.024","volume":"47","author":"CL Shapiro","year":"2011","unstructured":"Shapiro CL, Halabi S, Hars V, Archer L, Weckstein D, Kirshner J, Sikov W, Winer E, Burstein HJ, Hudis C et al (2011) Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer 47(5):683\u2013689","journal-title":"Eur J Cancer"},{"issue":"5","key":"1293_CR47","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/cncr.26313","volume":"118","author":"AM Brufsky","year":"2012","unstructured":"Brufsky AM, Harker WG, Beck JT, Bosserman L, Vogel C, Seidler C, Jin L, Warsi G, Argonza-Aviles E, Hohneker J et al (2012) Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer 118(5):1192\u20131201","journal-title":"Cancer"},{"issue":"3","key":"1293_CR48","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.bone.2012.05.010","volume":"51","author":"ST Chang","year":"2012","unstructured":"Chang ST, Tenforde AS, Grimsrud CD, O\u2019Ryan FS, Gonzalez JR, Baer DM, Chandra M, Lo JC (2012) Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy. Bone 51(3):524\u2013527","journal-title":"Bone"},{"issue":"4","key":"1293_CR49","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.breast.2012.04.008","volume":"21","author":"X Ding","year":"2012","unstructured":"Ding X, Fan Y, Ma F, Li Q, Wang J, Zhang P, Yuan P, Xu B (2012) Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis. Breast 21(4):544\u2013549","journal-title":"Breast"},{"issue":"1","key":"1293_CR50","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.clbc.2011.08.002","volume":"12","author":"A Llombart","year":"2012","unstructured":"Llombart A, Frassoldati A, Paija O, Sleeboom HP, Jerusalem G, Mebis J, Deleu I, Miller J, Schenk N, Neven P (2012) Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial. Clin Breast Cancer 12(1):40\u201348","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"1293_CR51","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s10549-012-1973-0","volume":"133","author":"S Takahashi","year":"2012","unstructured":"Takahashi S, Iwase T, Kohno N, Ishikawa T, Taguchi T, Takahashi M, Horiguchi J, Nakamura S, Hozumi Y, Fukunaga M et al (2012) Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results. Breast Cancer Res Treat 133(2):685\u2013693","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"1293_CR52","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/COC.0b013e3182155fcb","volume":"35","author":"V Thumbigere-Math","year":"2012","unstructured":"Thumbigere-Math V, Tu L, Huckabay S, Dudek AZ, Lunos S, Basi DL, Hughes PJ, Leach JW, Swenson KK, Gopalakrishnan R (2012) A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates. Am J Clin Oncol 35(4):386\u2013392","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"1293_CR53","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/annonc\/mds277","volume":"24","author":"R Coleman","year":"2013","unstructured":"Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P, von Minckwitz G, Sleeboom HP, Forbes J, Barrios C et al (2013) Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol Off J Eur Soc Med Oncol\/ESMO 24(2):398\u2013405","journal-title":"Ann Oncol Off J Eur Soc Med Oncol\/ESMO"}],"container-title":["European Journal of Orthopaedic Surgery &amp; Traumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00590-013-1293-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00590-013-1293-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00590-013-1293-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T02:18:18Z","timestamp":1563934698000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00590-013-1293-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,14]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["1293"],"URL":"https:\/\/doi.org\/10.1007\/s00590-013-1293-z","relation":{},"ISSN":["1633-8065","1432-1068"],"issn-type":[{"value":"1633-8065","type":"print"},{"value":"1432-1068","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,14]]}}}